You are here
NeuroMetrix Announces DPNCheck Collaboration Agreement with Fukuda Denshi for Japan Market
WALTHAM, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck®, the Company’s rapid, point-of-care test for diabetic peripheral neuropathy (DPN). The agreement provides Fukuda Denshi with exclusive distribution rights in Japan through March 31, 2021, subject to certain performance requirements.
Fukuda Denshi Co. Ltd., recently hosted a roundtable discussion in Tokyo on the clinical importance of early diagnosis of diabetic peripheral neuropathy, quantitative measurement, guidelines for staging of diabetic peripheral neuropathy for practical intervention, as well as appropriate tools for use in a clinical setting. Roundtable participants included leading Japanese academic clinicians and researchers, and Shai N. Gozani, M.D., Ph.D., NeuroMetrix, President and CEO.
“Fukuda Denshi has a significant presence in the healthcare professional market in Japan,” said Shai N. Gozani, M.D., Ph.D., NeuroMetrix President and CEO. “Their operating scale and commitment to expanding the use of DPNCheck are impressive. We look forward to growing the business together.”
DPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate diabetic peripheral neuropathy (DPN). It is designed to be used by clinicians at the point-of-care to objectively detect, stage, and monitor DPN. DPNCheck has been available since 2011 and over a million diagnostic tests worldwide have been performed using the technology. See DPNCheck.com for more information.
About Fukuda Denshi
Fukuda Denshi is a world leader in cardiology instrumentation, patient monitoring and ultrasound technologies. Fukuda Denshi creates medical technology with the purpose of providing relevant information easily, clearly, quickly, and reliably. Fukuda Denshi believes that technology must be transparent and dependable or it can confuse rather than clarify the patient's situation. Fukuda Denshi is listed on the JASDAQ Market of Tokyo Stock Exchange. For more information, please visit Fukuda Denshi.com.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The Company has two primary products. Quell® is an over-the-counter wearable therapeutic device for chronic pain. DPNCheck is a rapid point-of-care test for diabetic neuropathy which is the most common long-term complication of Type 2 diabetes. For more information, please visit www.NeuroMetrix.com.
Source: NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer